

## Women’s and Reproductive Health Guidelines Update Committee Meeting 36 (Day 1)

**Date:** 3 May 2023

**Location** Virtual via Microsoft Teams

**Minutes:** CONFIRMED

<b>Committee members present:</b>	
Sarah Fishburn (Chair)	Present for notes 1 – 9
Maggie Blott (Topic Advisor)	Present for notes 1 – 6
Maria Clark	Present for notes 1 – 6
Lucy O’Malley	Present for notes 1 – 6
Sarah Griffiths	Present for notes 1 – 6
Chimwemwe Kalumbi	Present for notes 1 – 9
Alena Chong	Present for notes 1 – 6
Cornelia Wiesender	Present for notes 1 – 6
Bryony Kendall	Present for notes 1 – 9
Frances Rivers	Present for notes 5 – 6
Sophie McAllister	Present for notes 1 – 5
Sophie House	Present for notes 5 – 6
Ashifa Trivedi	Present for notes 7 – 9
Aung Soe	Present for notes 1 – 6
Tim Watts	Present for notes 1 – 6
Neelam Potdar	Present for notes 7 – 9
Munira Oza	Present for notes 7 – 9
Ingrid Granne	Present for notes 7 – 9
Rachel Small	Present for notes 7 – 9

<b>In attendance:</b>		
Hilary Eadon	NICE Guideline Lead	Present for notes 1 – 9
Hayley Shaw	NICE Project Manager	Present for notes 1 – 9
Sharangini Rajesh	NICE Senior Technical Analyst	Present for notes 1 – 9
Agnesa Mehmeti	NICE Systematic Reviewer	Present for notes 1 – 9
Rebecca Blackburn	NICE Technical Analyst	Present for notes 1 – 9
Paul Jacklin	NICE Senior Health Economist	Present for notes 1 – 9
Ayisha Ashmore	Clinical Fellow	Present for notes 1 – 9
Suzie Panek	Finance Analyst	Present for notes 1 – 9

Gareth Haman	NICE Senior Medical Editor	Present for notes 1 – 9
Clifford Middleton	NICE Guideline Commissioning Manager	Present for notes 1 – 9

**Apologies:**

Stephanie Arnold	NICE Information Scientist
Catharine Baden Daintree	NICE Senior Medical Editor
Benjamin Gregory	NICE Business Analyst

**1. Welcome and objectives for the meeting.**

The chair welcomed the committee to the 36<sup>th</sup> Women’s and Reproductive Health guideline committee meeting (day 1).

The Chair informed the committee that apologies had been received as noted above.

The Chair outlined the objectives for the meeting, which included discussing updates to the caesarean birth and ectopic pregnancy and miscarriage guidelines.

**2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were women’s and reproductive health.

The Chair asked everyone to verbally declare any interests that have risen since the last meeting. New interests were declared and noted below.

Name	Role	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Bryony Kendall	Committee Member	Non-financial personal and professional interest	Member of UK Preconception Partnership University of Bristol GP member	19 <sup>th</sup> April 2023	27.03.2023	Ongoing	Declare and participate. Agreed by: GL May 2023 Rationale: Not specific to guideline
Neelam Potdar	Topic Advisor	Non-financial personal and professional interest	I was on the Data Monitoring Committee for the Mife-Miso RCT published in the Lancet and is the key published trial for this update.	October 2016	28.04.2023	13.03.2020	Declare and participate Agreed by: GL May 2023 Rationale: Role on data monitoring committee was during conduct of

							the trial, and would not have led to influence over published results. Role has now ended and so not a conflict with consideration of this study by the committee.
<b>3. Confirmation of matter under discussion, and declarations of interest</b>							
The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was caesarean birth.							
<b>4. Minutes of last meeting</b>							
The Chair asked the committee to confirm the minutes of the last meeting, and the committee confirmed that no changes were required.							
<b>5. Morning presentations</b>							
<p>The Chair introduced Hilary Eadon, Guideline Lead and Sarah Griffiths, Committee Member (obstetric anaesthetist), who led a discussion on CB2: Should NICE recommend an alternative to diamorphine for neuraxial analgesia after caesarean birth and does this change the monitoring requirements for women?</p> <p>Agnesa Mehmeti, Systematic Reviewer, presented clinical evidence for CB3: What is the most effective technique for the abdominal opening and subsequent extension of tissue layers in caesarean birth, including in overweight and obese women?</p>							
<b>6. Questions and discussions</b>							
<p>The committee discussed CB2 and edited current recommendations.</p> <p>The committee discussed the clinical evidence for CB3 and edited existing recommendations. They spoke about the rationale and impact for making these choices.</p>							
<b>7. Afternoon presentations</b>							
<p>The Chair welcomed members joining for the afternoon session and confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was the medical management of missed miscarriage. The Chair asked members joining for the afternoon session to verbally declare any interests that have risen since the last meeting. New interests were declared and noted above.</p> <p>The Chair outlined the objectives for the second part of the meeting, which included presenting clinical and economic evidence for EPM1 to the committee.</p> <p>The Chair introduced Rebecca Blackburn, Technical Analyst and Paul Jacklin, Senior Health Economist, who presented the evidence for EPM1: Is the combination of mifepristone and misoprostol more effective than misoprostol alone in the medical</p>							

management of missed miscarriage?

**8. Questions and discussions**

The committee discussed the evidence presented for EPM1 and edited existing recommendations. They spoke about the rationale and impact for making these choices.

**9. Any other business**

The meeting was closed at 17:00

**Date of next meeting:**

- Monday 19<sup>th</sup> and Wednesday 21<sup>st</sup> June (all day): Previous Obstetric committee members for IPC consultation comments
- Tuesday 18<sup>th</sup> July: Obstetric committee members committee meeting
- Week commencing 24<sup>th</sup> July (exact date tbc): Early pregnancy post consultation committee meeting (if required)

**Location of next meeting:** Virtual via Microsoft Teams